Erythropoietin (EPO) is produced primarily by peritubular interstitial cells in the renal cortex and outer medulla in response to hypoxia. The molecular mechanism by which renal hypoxia triggers EPO gene transcription involves:

• A HIF-1 (hypoxia-inducible factor): under normoxia, prolyl hydroxylases (PHDs) hydroxylate HIF-1alpha, targeting it for VHL-mediated ubiquitin-proteasome degradation; hypoxia inhibits PHDs, allowing HIF-1alpha stabilization and EPO transcription ✓
• B Direct oxygen sensing by a heme-containing protein kinase that activates JAK2-STAT5 signaling to drive EPO transcription
• C Adenosine release from ischemic renal cells activating A2B receptors on peritubular cells, triggering cAMP-mediated EPO gene expression
• D Angiotensin II released during renal ischemia acting on AT1 receptors to stimulate EPO promoter activity

Explanation

EPO gene expression is regulated by HIF (hypoxia-inducible factor). Under normoxic conditions, prolyl hydroxylase domain proteins (PHDs) hydroxylate specific proline residues on HIF-1alpha, creating a docking site for the VHL E3 ubiquitin ligase, which targets HIF-1alpha for proteasomal degradation. PHDs require molecular O2 as a substrate; when oxygen is low, PHD activity is reduced, HIF-1alpha is not hydroxylated and escapes degradation, dimerizes with HIF-1beta, and transactivates EPO and other hypoxia-response genes. This pathway is therapeutically exploited by HIF-PHD inhibitors (e.g., roxadustat) used in treating CKD-associated anemia.

Reference: Guyton & Hall, Textbook of Medical Physiology, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.